A reduced linezolid dosage maintains favorable efficacy with minimal hematologic toxicity in a methicillin-resistant Staphylococcus aureus-infected patient with renal insufficiency

Author: Taguchi Kazuaki   Miyakawa Toshikazu   Ohmura Takafumi   Horio Momoko   Anraku Yoshihisa   Okada Tatsuya   Mizuta Hiroshi   Saito Hideyuki   Kawaguchi Tatsuya  

Publisher: Informa Healthcare

ISSN: 0036-5548

Source: Scandinavian Journal of Infectious Diseases, Vol.45, Iss.1, 2013-01, pp. : 77-80

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

AbstractThe optimal dosage of linezolid to avoid hematologic toxicity is unknown. We report the case of an 87-y-old woman with renal insufficiency who developed a surgical site infection with refractory methicillin-resistant Staphylococcus aureus. The standard dosage of linezolid (1200 mg daily) was not initially tolerated by the patient due to severe thrombocytopenia, but she was successfully treated when the dose was reduced by half (600 mg daily) based on a population pharmacokinetic–pharmacodynamic model. Appropriate dose adjustments can be made to optimize linezolid therapy especially in cases with preexisting renal dysfunction.

Related content